Luzerner Kantonsspital - Luzern Trials

Luzerner Kantonsspital - Luzern	Welcome, Profile Billing Logout

67 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Gregor, Michael

HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting

777

Europe, RoW

Gilteritinib, ASP2215, Midostaurin, Rydapt

Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.

Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2

10/25

06/33

BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting

600

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

04/26

01/27

CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting

897

Europe, RoW

Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro

German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG), Janssen Pharmaceutica N.V., Belgium, AbbVie, Hoffmann-La Roche

Chronic Lymphoid Leukemia

09/27

Jin, Jie

NCT05177926: Preventing Mother-to-child Transmission of Hepatitis B Virus With Tenofovir Alafenamide (TAF)

Recruiting

330

RoW

antiviral prophylaxis with Tenofovir Alafenamide Fumarate

Nanfang Hospital of Southern Medical University, Gilead Sciences, Tigermed Consulting Co., Ltd

Hepatitis B, Chronic, Mother to Child Transmission

12/23

NCT05853718: Study of Tenofovir Alafenamide in HBV-Infected Pregnant Women

Recruiting

RoW

Tenofovir Alafenamide Tablets, TAF

First People's Hospital of Hangzhou

Chronic Hepatitis b, Tenofovir Alafenamide Fumarate

07/24

12/24

NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Active, not recruiting

RoW

Pomalidomide, Dexamethasone

Qilu Pharmaceutical Co., Ltd.

Multiple Myeloma, Recurrent or Refractory

06/22

12/23

PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

	Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
	Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
	Initiation of new trial in Ph+ ALL
	Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL

Active, not recruiting

245

Europe, Canada, Japan, US, RoW

Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone

Takeda

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

08/22

07/27

NCT05054543: Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML

Terminated

140

RoW

Uproleselan, GMI-1271, Placebo, Saline

Apollomics Inc., Zhejiang CrownMab Biotech Co. Ltd

Relapsed/Refractory AML

08/24

ZGJAK016, NCT04617028: Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis

Completed

105

RoW

Jaktinib, Placebo to match Hydroxycarbamide, Hydroxycarbamide Tablets, Placebo to match Jaktinib

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Myelofibrosis

10/23

NCT06361329: Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL

Recruiting

RoW

Homoharringtonine, venetoclax, Cytarabine, G-CSF, Vindesine, Daunorubicin, cyclophosphamide, Dexamethasone, L-ASP

First Affiliated Hospital of Zhejiang University

ETP-ALL

03/26

03/27

NCT06389292: A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

Recruiting

486

RoW

Lisaftoclax (APG-2575), Placebo, Azacitidine Injection

Ascentage Pharma Group Inc.

Acute Myeloid Leukemia

05/28

03/29

BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma

Recruiting

150

RoW

Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP

Beijing InnoCare Pharma Tech Co., Ltd.

Diffuse Large B Cell Lymphoma (DLBCL)

07/24

12/25

NCT06520163: Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma

Recruiting

RoW

Etoposide, VP-16, Cytarabine, Ara-C, PEG-rhG-CSF, G-CSF, CHOP, Hyper-CVAD, ID-MTX + Ara-C, DA-EPOCH, GDP, GDPE, ICE, DICE

The Affiliated People's Hospital of Ningbo University, First Affiliated Hospital of Zhejiang University, First Affiliated Hospital of Wenzhou Medical University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Jinhua People's Hospital, The Central Hospital of Lishui City, Shaoxing People's Hospital, Shaoxing Second Hospital, Zhejiang Provincial Tongde Hospital, Taizhou Hospital, Dongyang People's Hospital, Affiliated Hospital of Jiaxing University, Huizhou Municipal Central Hospital, Second Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Hospital, Jinhua Municipal Central Hospital

Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization

12/26

NCT06520176: Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

Recruiting

RoW

Etoposide, VP-16, Cytarabine, Ara-C, Pegfilgrastim, PEG-rhG-CSF, Cyclophosphamide, Cy, G-CSF, Granulocyte Colony Stimulating Factor

The Affiliated People's Hospital of Ningbo University, First Affiliated Hospital of Zhejiang University, First Affiliated Hospital of Wenzhou Medical University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, The Central Hospital of Lishui City, Jinhua People's Hospital, Shaoxing People's Hospital, Shaoxing Second Hospital, Zhejiang Provincial Tongde Hospital, Taizhou Hospital, Dongyang People's Hospital, Affiliated Hospital of Jiaxing University, Huizhou Municipal Central Hospital, Second Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Hospital, Jinhua Municipal Central Hospital

Multiple Myeloma, Hematopoietic Stem Cell Mobilization

12/26

NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

Recruiting

218

RoW

ICP-022, Chlorambucil, Rituximab

Beijing InnoCare Pharma Tech Co., Ltd.

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

12/24

06/25

NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

Recruiting

356

RoW

Orelabrutinib and R-CHOP, R-CHOP

Beijing InnoCare Pharma Tech Co., Ltd.

Treatment-naїve Mantle Cell Lymphoma

12/24

12/27

LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

	Jun 2025 - Jun 2025 : Updated safety run-in data for 2L+ r/r DLBCL/HGBL
	Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
	Sep 2021 - Dec 2021 : Submission for r/r DLBCL

Active, not recruiting

440

Europe, Canada, Japan, US, RoW

Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin

ADC Therapeutics S.A., ADC Therapeutics SA

Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

06/25

06/28

Active, not recruiting

600

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

04/26

01/27

NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia

Recruiting

195

RoW

Orelabrutinib, Placebo

Beijing InnoCare Pharma Tech Co., Ltd.

Chronic Primary Immune Thrombocytopenia (ITP)

12/25

04/26

NCT05586074: HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

Recruiting

324

RoW

Clifutinib, HEC73543, LoDAC, Low Dose Cytarabine, Azacitidine, Decitabine, Ara-C±IDA, Cytarabine, Idarubicin, FLAG-IDA, Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin

Sunshine Lake Pharma Co., Ltd.

Leukemia, Acute Myeloid (AML)

03/26

06/27

BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

725

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

06/25

01/28

JACKPOT26, NCT06511869: AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy

Active, not recruiting

130

RoW

AZD4205

Dizal Pharmaceuticals

Peripheral T-cell Lymphoma

03/25

03/26

NCT04233346: The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

Active, not recruiting

RoW

Ponatinib 30mg OD, Ponatinib 45mg OD

Otsuka Beijing Research Institute

Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia

07/22

12/25

ZGJAK006, NCT04217993: Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

Completed

RoW

Jaktinib hydrochloride tablets, Jaktinib

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis(Post-PV MF), Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)

08/22

NCT04684147: Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

Recruiting

100

RoW

single dose of CNCT19

Juventas Cell Therapy Ltd.

Relapsed or Refractory Acute Lymphoblastic Leukemia

09/22

12/26

NCT04851535: Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.

Completed

RoW

Jaktinib Hydrochloride Tablets

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Myelofibrosis

11/22

NCT04438005: A Study of ICP-022 in Patients With R/R DLBCL

Completed

RoW

ICP-022

Beijing InnoCare Pharma Tech Co., Ltd.

Diffuse Large B Cell Lymphoma

11/21

12/21

JWCAR029-005, NCT04718883: CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Active, not recruiting

RoW

CD19-targeted Chimeric Antigen Receptor (CAR) T Cells

Shanghai Ming Ju Biotechnology Co., Ltd.

Mantle Cell Lymphoma

10/23

08/28

NCT05147467: Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Recruiting

RoW

APG2575

Ascentage Pharma Group Inc.

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

09/24

12/24

NCT04586478: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting

RoW

single dose of CNCT19

Juventas Cell Therapy Ltd.

Non-Hodgkin's Lymphoma

03/24

09/25

NCT06434662: Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML

Recruiting

RoW

mitoxantrone hydrochloride liposome, Cytarabine, Venetoclax

First Affiliated Hospital of Zhejiang University, CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy

06/25

06/26

NCT06621199: Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML

Recruiting

RoW

Mitoxantrone hydrochloride liposome, Cytarabine, Venetoclax

First Affiliated Hospital of Zhejiang University, CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Acute Myeloid Leukemia

12/27

NCT06093841: Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

Active, not recruiting

RoW

Relmacabtagene Autoleucel, JWCAR029, Fludarabine, Cyclophosphamide

Shanghai Ming Ju Biotechnology Co., Ltd.

Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma

01/24

11/29

NCT06554626: Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL

Recruiting

RoW

Dexamethasone, Blinatumomab, Blina, Venetoclax, Ven, Inotuzumab ozogamicin, INO, Methotrexate, MTX, Pegaspargase, PEG, Cytarabine, Ara-C

First Affiliated Hospital of Zhejiang University

Precursor B-Cell Lymphoblastic Leukemia

08/26

08/27

GR1803-002, NCT06566547: GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting

116

RoW

GR1803 injection

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Multiple Myeloma

08/26

08/27

NCT06742515: Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL

Recruiting

RoW

Blinatumomab plus Reduced-dose Chemotherapy

First Affiliated Hospital of Zhejiang University

Precursor B-Cell Acute Lymphoblastic Leukemia

10/26

08/28

NCT06754267: Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL

Recruiting

RoW

Venetoclax, Ven, Olverembatinib, Olv, Predinisone

First Affiliated Hospital of Zhejiang University

Precursor B-Cell Acute Lymphoblastic Leukemia

12/25

12/27

NCT06742463: VHAG in Treating R/R T-ALL/LBL

Recruiting

RoW

Venetoclax, homoharringtonine, Cytarabine (Ara-C), G-CSF

First Affiliated Hospital of Zhejiang University

Acute T Lymphpblastic Leukemia/Lymphoma

06/26

06/28

ICP-CL-00901, NCT05552937: Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Recruiting

RoW

Tafasitamab and Lenalidomide

Beijing InnoCare Pharma Tech Co., Ltd.

DLBCL

04/25

04/27

NCT03994913: Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma

Completed

1/2

RoW

CAR-CD19 T Cells

CARsgen Therapeutics Co., Ltd., First Affiliated Hospital of Zhejiang University, RenJi Hospital

Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed B-cell Non-Hodgkin Lymphoma

01/21

05/21

AK117-104, NCT04980885: A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia

Active, not recruiting

1/2

RoW

AK117, Azacitidine

Akeso

Acute Myeloid Leukemia

09/25

12/25

NCT05611853: Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Terminated

1/2

RoW

BN301, STRO-001

BioNova Pharmaceuticals (Shanghai) LTD.

B-cell Lymphoma, Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma

12/23

APG2575AC101, NCT04501120: Study of APG2575 Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Recruiting

1/2

284

RoW

APG-2575, Reduced-dose HHT, standard-dose HHT, Azacitidine

Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.

Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy

08/25

08/26

NCT06580301: Study of YK012 in B-cell Acute Lymphoblastic Leukemia

Recruiting

1/2

RoW

YK012, YK012 for Injection

Excyte Biopharma Ltd

B-cell Acute Lymphoblastic Leukemia

12/26

06/27

NCT04494503: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Recruiting

1/2

123

RoW

APG-2575, Rituximab, Ibrutinib

Ascentage Pharma Group Inc.

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

10/24

12/25

NCT05133882: A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML

Recruiting

1/2

133

RoW

Clifutinib Besylate, HEC73543

Sunshine Lake Pharma Co., Ltd.

Acute Myeloid Leukemia, Adult

05/26

08/26

NCT05565807: Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Recruiting

1/2

RoW

STI-6129

Zhejiang ACEA Pharmaceutical Co. Ltd.

Relapsed or Refractory Multiple Myeloma

03/25

02/27

NCT06883526: Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma

Not yet recruiting

1/2

RoW

ZG005 for Injection, ZG005, Gecacitinib Hydrochloride Tablets, Gecacitinib

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Lymphoma

04/27

05/27

NCT06091267: PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes

Active, not recruiting

1/2

RoW

IV Decitabine, Decitabine and cedazuridine, only Decitabine and cedazuridine

Otsuka Beijing Research Institute

Myelodysplastic Syndromes

12/25

06/26

ELEVATION, NCT05800977: A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Recruiting

1/2

112

RoW

Prizloncabtagene autoleucel, C-CAR039

Shanghai AbelZeta Ltd.

Relapsed/Refractory Large B-Cell Lymphoma

10/25

12/27

NCT03716856: Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma

Active, not recruiting

RoW

CAR-BCMA T cells, BCMA-redirected autologous T cells, Fludarabine, Cyclophosphamide

First Affiliated Hospital of Zhejiang University, CARsgen Therapeutics Co., Ltd.

Refractory or Relapsed Multiple Myeloma

06/20

06/23

NCT04486872: An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection

Recruiting

RoW

Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells

First Affiliated Hospital of Zhejiang University

Diffuse Large B Cell Lymphoma

05/22

06/22

NCT04827069: A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML)

Completed

RoW

Clifutinib Besylate, HEC73543

Sunshine Lake Pharma Co., Ltd.

Acute Myeloid Leukemia

08/23

NCT04839341: Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients

Completed

RoW

Uproleselan, GMI-1271

Apollomics Inc., Zhejiang CrownMab Biotech Co. Ltd

Relapsed/Refractory AML

06/24

NCT04689308: This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies

Recruiting

RoW

MH048, MH048 Soft Gel Capsules

Minghui Pharmaceutical (Shanghai) LTD

Relapsed/Refractory B-cell Malignancies

06/23

10/23

NCT04693676: A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma

Active, not recruiting

RoW

Prizloncabtagene Autoleucel, C-CAR039

First Affiliated Hospital of Zhejiang University, Cellular Biomedicine Group Ltd.

Non-Hodgkin's B-cell Lymphoma

12/23

04/24

NCT06387082: A Clinical Study of HMPL-506 in Patients With Hematological Malignancies

Recruiting

132

RoW

HMPL-506, Two strengths of HMPL-506 tablets (25 mg and 100 mg) will be used for this clinical study

Hutchmed

Hematological Malignancies

10/27

12/27

NCT06574568: A Study of YKST02 in Participants with Relapsed or Refractory Multiple Myeloma

Recruiting

RoW

YKST02, YKST02 for Injection

Excyte Biopharma Ltd

Relapsed or Refractory Multiple Myeloma

12/26

06/27

NCT05650580: TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors

Recruiting

RoW

TR115

Tarapeutics Science Inc.

Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Advanced Solid Tumor

07/25

12/25

ICP-CL-01201, NCT05728658: The Study of ICP-248 in Patients with Mature B-cell Malignancies

Recruiting

191

RoW

ICP-248, ICP-248+Orelabrutinib

Beijing InnoCare Pharma Tech Co., Ltd.

Hematological Malignancies

08/25

10/26

NCT07014449: Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia

Recruiting

RoW

WBC100 QD

Hangzhou Weben Pharma Co., Ltd

AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia, Refractory Acute Myeloid Leukemia, Hematologic Malignancy, C-Myc, Adult Acute Myeloid Leukemia

06/26

ICP-CL-01205, NCT06656494: ICP-248 in Combination with Azacitidine in Treatment-Naïve Subjects with Acute Myelogenous Leukemia(AML) or Previously Treated Relapsed/Refractory Subjects with Acute Myelogenous Leukemia(R/R AML).

Recruiting

102

RoW

ICP-248, Azacitidine

Beijing InnoCare Pharma Tech Co., Ltd.

Acute Myelogenous Leukemia

06/27

01/28

NCT06705725: Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma

Not yet recruiting

CBG002 CAR-T Cell Suspension

Carbiogene Therapeutics Co. Ltd.

Multiple Myeloma

10/27

02/28

MAPLE-1, NCT04260217: APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia

Completed

US, RoW

APG2575 400 mg, APG2575 600 mg, APG2575 800 mg

Ascentage Pharma Group Inc.

Waldenstrom Macroglobulinemia

02/24

NCT05947344: A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)

Recruiting

RoW

STI-8591, STI-8591 alone

Zhejiang ACEA Pharmaceutical Co. Ltd.

AML, Adult

12/25

DILI-P, NCT02961413: A Prospective Cohort Study on Drug-induced Liver Injury in China（）

Recruiting

N/A

10000

RoW

Drug Induced Liver Disease Study Group

Drug-induced Liver Injury

12/30

NCT06621212: Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML

Recruiting

N/A

RoW

mitoxantrone hydrochloride liposome, Cytarabine, Venetoclax

First Affiliated Hospital of Zhejiang University, CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy

12/25

12/26

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Gregor, Michael

Active, not recruiting

777

Europe, RoW

Gilteritinib, ASP2215, Midostaurin, Rydapt

Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.

Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2

10/25

06/33

Active, not recruiting

600

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

04/26

01/27

Active, not recruiting

897

Europe, RoW

Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro

Chronic Lymphoid Leukemia

09/27

Jin, Jie

NCT05177926: Preventing Mother-to-child Transmission of Hepatitis B Virus With Tenofovir Alafenamide (TAF)

Recruiting

330

RoW

antiviral prophylaxis with Tenofovir Alafenamide Fumarate

Nanfang Hospital of Southern Medical University, Gilead Sciences, Tigermed Consulting Co., Ltd

Hepatitis B, Chronic, Mother to Child Transmission

12/23

NCT05853718: Study of Tenofovir Alafenamide in HBV-Infected Pregnant Women

Recruiting

RoW

Tenofovir Alafenamide Tablets, TAF

First People's Hospital of Hangzhou

Chronic Hepatitis b, Tenofovir Alafenamide Fumarate

07/24

12/24

NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Active, not recruiting

RoW

Pomalidomide, Dexamethasone

Qilu Pharmaceutical Co., Ltd.

Multiple Myeloma, Recurrent or Refractory

06/22

12/23

PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

	Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
	Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
	Initiation of new trial in Ph+ ALL
	Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL

Active, not recruiting

245

Europe, Canada, Japan, US, RoW

Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone

Takeda

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

08/22

07/27

NCT05054543: Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML

Terminated

140

RoW

Uproleselan, GMI-1271, Placebo, Saline

Apollomics Inc., Zhejiang CrownMab Biotech Co. Ltd

Relapsed/Refractory AML

08/24

ZGJAK016, NCT04617028: Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis

Completed

105

RoW

Jaktinib, Placebo to match Hydroxycarbamide, Hydroxycarbamide Tablets, Placebo to match Jaktinib

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Myelofibrosis

10/23

NCT06361329: Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL

Recruiting

RoW

Homoharringtonine, venetoclax, Cytarabine, G-CSF, Vindesine, Daunorubicin, cyclophosphamide, Dexamethasone, L-ASP

First Affiliated Hospital of Zhejiang University

ETP-ALL

03/26

03/27

NCT06389292: A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

Recruiting

486

RoW

Lisaftoclax (APG-2575), Placebo, Azacitidine Injection

Ascentage Pharma Group Inc.

Acute Myeloid Leukemia

05/28

03/29

BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma

Recruiting

150

RoW

Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP

Beijing InnoCare Pharma Tech Co., Ltd.

Diffuse Large B Cell Lymphoma (DLBCL)

07/24

12/25

NCT06520163: Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma

Recruiting

RoW

Etoposide, VP-16, Cytarabine, Ara-C, PEG-rhG-CSF, G-CSF, CHOP, Hyper-CVAD, ID-MTX + Ara-C, DA-EPOCH, GDP, GDPE, ICE, DICE

Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization

12/26

NCT06520176: Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

Recruiting

RoW

Etoposide, VP-16, Cytarabine, Ara-C, Pegfilgrastim, PEG-rhG-CSF, Cyclophosphamide, Cy, G-CSF, Granulocyte Colony Stimulating Factor

The Affiliated People's Hospital of Ningbo University, First Affiliated Hospital of Zhejiang University, First Affiliated Hospital of Wenzhou Medical University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, The Central Hospital of Lishui City, Jinhua People's Hospital, Shaoxing People's Hospital, Shaoxing Second Hospital, Zhejiang Provincial Tongde Hospital, Taizhou Hospital, Dongyang People's Hospital, Affiliated Hospital of Jiaxing University, Huizhou Municipal Central Hospital, Second Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Hospital, Jinhua Municipal Central Hospital

Multiple Myeloma, Hematopoietic Stem Cell Mobilization

12/26

NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL

Recruiting

218

RoW

ICP-022, Chlorambucil, Rituximab

Beijing InnoCare Pharma Tech Co., Ltd.

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

12/24

06/25

Recruiting

356

RoW

Orelabrutinib and R-CHOP, R-CHOP

Beijing InnoCare Pharma Tech Co., Ltd.

Treatment-naїve Mantle Cell Lymphoma

12/24

12/27

LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

	Jun 2025 - Jun 2025 : Updated safety run-in data for 2L+ r/r DLBCL/HGBL
	Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
	Sep 2021 - Dec 2021 : Submission for r/r DLBCL

Active, not recruiting

440

Europe, Canada, Japan, US, RoW

Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin

ADC Therapeutics S.A., ADC Therapeutics SA

Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

06/25

06/28

Active, not recruiting

600

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

04/26

01/27

NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia

Recruiting

195

RoW

Orelabrutinib, Placebo

Beijing InnoCare Pharma Tech Co., Ltd.

Chronic Primary Immune Thrombocytopenia (ITP)

12/25

04/26

NCT05586074: HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

Recruiting

324

RoW

Sunshine Lake Pharma Co., Ltd.

Leukemia, Acute Myeloid (AML)

03/26

06/27

BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting

725

Europe, Canada, Japan, US, RoW

Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib

Loxo Oncology, Inc., Eli Lilly and Company

Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

06/25

01/28

JACKPOT26, NCT06511869: AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy

Active, not recruiting

130

RoW

AZD4205

Dizal Pharmaceuticals

Peripheral T-cell Lymphoma

03/25

03/26

NCT04233346: The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

Active, not recruiting

RoW

Ponatinib 30mg OD, Ponatinib 45mg OD

Otsuka Beijing Research Institute

Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia

07/22

12/25

ZGJAK006, NCT04217993: Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

Completed

RoW

Jaktinib hydrochloride tablets, Jaktinib

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis(Post-PV MF), Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)

08/22

NCT04684147: Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

Recruiting

100

RoW

single dose of CNCT19

Juventas Cell Therapy Ltd.

Relapsed or Refractory Acute Lymphoblastic Leukemia

09/22

12/26

NCT04851535: Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.

Completed

RoW

Jaktinib Hydrochloride Tablets

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Myelofibrosis

11/22

NCT04438005: A Study of ICP-022 in Patients With R/R DLBCL

Completed

RoW

ICP-022

Beijing InnoCare Pharma Tech Co., Ltd.

Diffuse Large B Cell Lymphoma

11/21

12/21

JWCAR029-005, NCT04718883: CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Active, not recruiting

RoW

CD19-targeted Chimeric Antigen Receptor (CAR) T Cells

Shanghai Ming Ju Biotechnology Co., Ltd.

Mantle Cell Lymphoma

10/23

08/28

NCT05147467: Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Recruiting

RoW

APG2575

Ascentage Pharma Group Inc.

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

09/24

12/24

NCT04586478: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting

RoW

single dose of CNCT19

Juventas Cell Therapy Ltd.

Non-Hodgkin's Lymphoma

03/24

09/25

NCT06434662: Mitoxantrone Hydrochloride Liposome Injection, Cytarabine Combined With Venetoclax in the Treatment of R/R AML

Recruiting

RoW

mitoxantrone hydrochloride liposome, Cytarabine, Venetoclax

First Affiliated Hospital of Zhejiang University, CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy

06/25

06/26

NCT06621199: Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML

Recruiting

RoW

Mitoxantrone hydrochloride liposome, Cytarabine, Venetoclax

First Affiliated Hospital of Zhejiang University, CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Acute Myeloid Leukemia

12/27

NCT06093841: Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

Active, not recruiting

RoW

Relmacabtagene Autoleucel, JWCAR029, Fludarabine, Cyclophosphamide

Shanghai Ming Ju Biotechnology Co., Ltd.

Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma

01/24

11/29

NCT06554626: Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL

Recruiting

RoW

Dexamethasone, Blinatumomab, Blina, Venetoclax, Ven, Inotuzumab ozogamicin, INO, Methotrexate, MTX, Pegaspargase, PEG, Cytarabine, Ara-C

First Affiliated Hospital of Zhejiang University

Precursor B-Cell Lymphoblastic Leukemia

08/26

08/27

GR1803-002, NCT06566547: GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting

116

RoW

GR1803 injection

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Multiple Myeloma

08/26

08/27

NCT06742515: Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL

Recruiting

RoW

Blinatumomab plus Reduced-dose Chemotherapy

First Affiliated Hospital of Zhejiang University

Precursor B-Cell Acute Lymphoblastic Leukemia

10/26

08/28

NCT06754267: Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL

Recruiting

RoW

Venetoclax, Ven, Olverembatinib, Olv, Predinisone

First Affiliated Hospital of Zhejiang University

Precursor B-Cell Acute Lymphoblastic Leukemia

12/25

12/27

NCT06742463: VHAG in Treating R/R T-ALL/LBL

Recruiting

RoW

Venetoclax, homoharringtonine, Cytarabine (Ara-C), G-CSF

First Affiliated Hospital of Zhejiang University

Acute T Lymphpblastic Leukemia/Lymphoma

06/26

06/28

ICP-CL-00901, NCT05552937: Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Recruiting

RoW

Tafasitamab and Lenalidomide

Beijing InnoCare Pharma Tech Co., Ltd.

DLBCL

04/25

04/27

NCT03994913: Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma

Completed

1/2

RoW

CAR-CD19 T Cells

CARsgen Therapeutics Co., Ltd., First Affiliated Hospital of Zhejiang University, RenJi Hospital

Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed B-cell Non-Hodgkin Lymphoma

01/21

05/21

AK117-104, NCT04980885: A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia

Active, not recruiting

1/2

RoW

AK117, Azacitidine

Akeso

Acute Myeloid Leukemia

09/25

12/25

NCT05611853: Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Terminated

1/2

RoW

BN301, STRO-001

BioNova Pharmaceuticals (Shanghai) LTD.

B-cell Lymphoma, Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma

12/23

APG2575AC101, NCT04501120: Study of APG2575 Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Recruiting

1/2

284

RoW

APG-2575, Reduced-dose HHT, standard-dose HHT, Azacitidine

Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd.

Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy

08/25

08/26

NCT06580301: Study of YK012 in B-cell Acute Lymphoblastic Leukemia

Recruiting

1/2

RoW

YK012, YK012 for Injection

Excyte Biopharma Ltd

B-cell Acute Lymphoblastic Leukemia

12/26

06/27

NCT04494503: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Recruiting

1/2

123

RoW

APG-2575, Rituximab, Ibrutinib

Ascentage Pharma Group Inc.

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

10/24

12/25

NCT05133882: A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML

Recruiting

1/2

133

RoW

Clifutinib Besylate, HEC73543

Sunshine Lake Pharma Co., Ltd.

Acute Myeloid Leukemia, Adult

05/26

08/26

NCT05565807: Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Recruiting

1/2

RoW

STI-6129

Zhejiang ACEA Pharmaceutical Co. Ltd.

Relapsed or Refractory Multiple Myeloma

03/25

02/27

NCT06883526: Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma

Not yet recruiting

1/2

RoW

ZG005 for Injection, ZG005, Gecacitinib Hydrochloride Tablets, Gecacitinib

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Lymphoma

04/27

05/27

NCT06091267: PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes

Active, not recruiting

1/2

RoW

IV Decitabine, Decitabine and cedazuridine, only Decitabine and cedazuridine

Otsuka Beijing Research Institute

Myelodysplastic Syndromes

12/25

06/26

ELEVATION, NCT05800977: A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Recruiting

1/2

112

RoW

Prizloncabtagene autoleucel, C-CAR039

Shanghai AbelZeta Ltd.

Relapsed/Refractory Large B-Cell Lymphoma

10/25

12/27

NCT03716856: Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma

Active, not recruiting

RoW

CAR-BCMA T cells, BCMA-redirected autologous T cells, Fludarabine, Cyclophosphamide

First Affiliated Hospital of Zhejiang University, CARsgen Therapeutics Co., Ltd.

Refractory or Relapsed Multiple Myeloma

06/20

06/23

NCT04486872: An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection

Recruiting

RoW

Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells

First Affiliated Hospital of Zhejiang University

Diffuse Large B Cell Lymphoma

05/22

06/22

NCT04827069: A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML)

Completed

RoW

Clifutinib Besylate, HEC73543

Sunshine Lake Pharma Co., Ltd.

Acute Myeloid Leukemia

08/23

NCT04839341: Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients

Completed

RoW

Uproleselan, GMI-1271

Apollomics Inc., Zhejiang CrownMab Biotech Co. Ltd

Relapsed/Refractory AML

06/24

NCT04689308: This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies

Recruiting

RoW

MH048, MH048 Soft Gel Capsules

Minghui Pharmaceutical (Shanghai) LTD

Relapsed/Refractory B-cell Malignancies

06/23

10/23

NCT04693676: A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma

Active, not recruiting

RoW

Prizloncabtagene Autoleucel, C-CAR039

First Affiliated Hospital of Zhejiang University, Cellular Biomedicine Group Ltd.

Non-Hodgkin's B-cell Lymphoma

12/23

04/24

NCT06387082: A Clinical Study of HMPL-506 in Patients With Hematological Malignancies

Recruiting

132

RoW

HMPL-506, Two strengths of HMPL-506 tablets (25 mg and 100 mg) will be used for this clinical study

Hutchmed

Hematological Malignancies

10/27

12/27

NCT06574568: A Study of YKST02 in Participants with Relapsed or Refractory Multiple Myeloma

Recruiting

RoW

YKST02, YKST02 for Injection

Excyte Biopharma Ltd

Relapsed or Refractory Multiple Myeloma

12/26

06/27

NCT05650580: TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors

Recruiting

RoW

TR115

Tarapeutics Science Inc.

Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Advanced Solid Tumor

07/25

12/25

ICP-CL-01201, NCT05728658: The Study of ICP-248 in Patients with Mature B-cell Malignancies

Recruiting

191

RoW

ICP-248, ICP-248+Orelabrutinib

Beijing InnoCare Pharma Tech Co., Ltd.

Hematological Malignancies

08/25

10/26

NCT07014449: Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia

Recruiting

RoW

WBC100 QD

Hangzhou Weben Pharma Co., Ltd

AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia, Refractory Acute Myeloid Leukemia, Hematologic Malignancy, C-Myc, Adult Acute Myeloid Leukemia

06/26

Recruiting

102

RoW

ICP-248, Azacitidine

Beijing InnoCare Pharma Tech Co., Ltd.

Acute Myelogenous Leukemia

06/27

01/28

NCT06705725: Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma

Not yet recruiting

CBG002 CAR-T Cell Suspension

Carbiogene Therapeutics Co. Ltd.

Multiple Myeloma

10/27

02/28

MAPLE-1, NCT04260217: APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia

Completed

US, RoW

APG2575 400 mg, APG2575 600 mg, APG2575 800 mg

Ascentage Pharma Group Inc.

Waldenstrom Macroglobulinemia

02/24

NCT05947344: A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)

Recruiting

RoW

STI-8591, STI-8591 alone

Zhejiang ACEA Pharmaceutical Co. Ltd.

AML, Adult

12/25

DILI-P, NCT02961413: A Prospective Cohort Study on Drug-induced Liver Injury in China（）

Recruiting

N/A

10000

RoW

Drug Induced Liver Disease Study Group

Drug-induced Liver Injury

12/30

NCT06621212: Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML

Recruiting

N/A

RoW

mitoxantrone hydrochloride liposome, Cytarabine, Venetoclax

First Affiliated Hospital of Zhejiang University, CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy

12/25

12/26

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites